NASDAQ$QDEL

Quidel Corp · Q1 2026 earnings

Q1 2026 earnings · · After market close · Investor relations

Briefing

QuidelOrtho reported Q1 2026 total revenues of $619.8M (-11% YoY) and a net loss of $91.8M, or $1.35 diluted EPS, on weaker respiratory and Joint Business headwinds.

Total revenues fell 11% to $619.8 million for the quarter ended March 29, 2026, as respiratory assay sales declined and the terminated Joint Business reduced Labs revenue. Net loss widened to $91.8 million, or $1.35 per share, from $12.7 million; cost of sales rose to 57.4% of revenue on mix and compensation.

  • Total revenues $619.8M (-11% YoY).
  • Respiratory products 11% of revenue vs 17% prior year.
  • Net loss $91.8M; diluted EPS $(1.35).
  • Labs revenue down on Joint Business termination ($13.3M impact).

Headline financials

Total Revenue

$620M

Previous: $693M-10.5%
EPS (adj)

-$1.35

Previous: $0.19-810.5%
Capital Expenditures

-$34M

Previous: -$56.2M+39.5%
Net Income

-$91.8M

Previous: -$12.7M-622.8%

Revenue & EPS history

Quidel · Revenue · Quarterly

$620M

Q1 2026-10.5%vs Q1 2025
Beat estimate in 2 of 2 quarters(100%)
ActualEstimate

Forward guidance

The 10-Q does not provide numeric consolidated annual EPS guidance for QDEL. Management commentary in MD&A covers costs, capital, and sector-specific risks.

Tailwinds

  • Management discusses operational priorities and liquidity in the quarterly filing.
  • Segment or product trends are disclosed where applicable to the business model.

Headwinds

  • Macro, input-cost, and interest-rate exposure can affect near-term results.
  • One-time items, impairments, or fair-value marks may distort quarterly comparability.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 12 quarterly earnings reports · overlaid with Q1 2026

Historical avgQ1 2026

-3.1%

Avg return

Earnings day

-0.1%

Avg return

5 days after

+0.8%

Avg return

30 days after

17%

2 / 12 earnings

Positive

+6.9%

Q2 2024

Best reaction

-17.6%

Q4 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-6.0%-14.8%+22.8%
Q4 2025-17.6%-19.7%-40.6%
Q3 2025-4.3%+6.3%+30.6%
Q1 2025-0.3%+44.3%+13.8%
Q3 2024-2.8%+3.0%-4.4%
Q2 2024+6.9%+2.0%+7.5%
Q1 2024-2.7%-4.0%-5.0%
Q3 2023-0.9%+2.9%+13.3%
Q2 2023-2.0%-7.1%-9.8%
Q1 2023-6.5%-7.7%-7.6%
Q3 2022+3.8%+0.1%+7.7%
Q2 2022-5.1%-6.3%-19.2%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro